Health & Biotech
ECS Botantics (ASX:ECS) have a proud Tasmanian heritage. Their industrial hemp seed is grown from their farm in the pristine midlands of Tasmania, known for its clean air and rich fertile soils, producing the finest foods.
Tasmanian climate and soils of the region combine to create ideal growing conditions, producing a depth and consistency of secondary metabolites in cannabis ie THC, CBD, Terpenes.
ECS prides itself on building strong relationships with farmers, suppliers and manufacturers.
The company’s product portfolio, specialised supply chain and best of breed farmer network, position them to be a leading player in the Australian hemp market.
They believe in changing the world through hemp and in supporting a healthy planet with sustainable products which will enable people to live better, healthier lives.
KEY PEOPLE
RELATED STOCKHEAD STORIES
Health & Biotech
Weed Week: Cannabis-feed for chickens and cannabis campaigner nabs Queen’s Birthday honour
Health & Biotech
ECS delivers 450% PCP growth in Q3 revenue, targets UK and European giants as new frontiers for its homegrown cannabis
News
Weed Week: New Yorkers with cannabis convictions first in line for retail licences, CBX Stock Exchange launches
Health & Biotech
Australian dried cannabis flower high: ECS shares jump on massive Q3 revenue update
Health & Biotech
Here’s to you ECS investors: Shares rise as ECS Botanics delivers 300% surge in half year revenue
Health & Biotech
The UK’s love affair with Aussie medicinal cannabis blooms as ECS exports first dried flower shipment
Health & Biotech
ASX Health Stocks: Opthea presents data at global conference; CardieX to progress Philip Morris sponsored study
News
Market highlights and 5 ASX small caps to watch on Monday
Health & Biotech
ECS Botanics doesn’t miss a beat with more strong revenue growth as momentum continues to build
Health & Biotech
Weed Week: Cannabis compounds could prevent Covid and Quebec’s no-jab, no-weed rule quadruples vaccinations
Health & Biotech
Shares flying under the radar? Another revenue surge locks in ECS Botanics as Australia’s top cannabis supplier
Health & Biotech
ASX Health Stocks: Immuron up 29pc on $6.2m travellers’ diarrhoea clinical study for US military
News
Market Highlights and 5 ASX Small Caps to watch on Wednesday
Health & Biotech
ECS stock rises on $4.9 million Cannvalate supply deal
Health & Biotech
ASX Health: 4D Medical jumps 16pc on lungs device rollout, Proteomics up 10pc on UK deal
Health & Biotech
ASX pot stocks tap the capital markets as ECS and Cann Global announce capital raisings
Stockhead TV